Skip to main content

Vie Ventures

Accelerating Innovation by Partnering with Venture Capital

The Scleroderma Research Foundation (SRF) is proud to be a Strategic Collaborator in Vie Ventures, an impact fund co-launched by SRF Board Chairman Luke Evnin, PhD and Steven St. Peter, MD to advance innovative therapeutics for autoimmune diseases.

This alliance puts scleroderma on a bigger stage by elevating visibility within the biotech sector, building cross-community connections with foundations across related diseases and creates new opportunities to strengthen our research program. By connecting scientific innovation with strategic investment, Vie Ventures helps accelerate the development of promising treatments that have the potential to improve patient outcomes.

Why It Matters

Developing new treatments requires funding, collaboration, and support to move promising research forward. Through partnerships like Vie Ventures, we can help accelerate the translation of research into real-world solutions for patients.

The Latest News & Updates About Vie Ventures

Research
February 19, 2026
Renowned Immunologist Jeff Bluestone, PhD Joins Vie Ventures
The Scleroderma Research Foundation (SRF) welcomes the news that renowned immunologist Jeff Bluestone, PhD, has been named Managing Director at Vie Ventures—a biotech venture capital firm that advances therapies for autoimmune and immune-mediated diseases, including scleroderma. The firm was co-founded by SRF Board Chairman Luke Evnin, PhD, and Steven St. Peter, MD Dr. Bluestone is...
Research
January 28, 2026
Vie Ventures Convenes Immunology Community in San Francisco
For decades, scientists have worked to understand one of the immune system’s most complex players: regulatory T cells (Tregs). Long recognized for their potential to restore immune balance, Tregs have remained difficult to define and fully translate into real-world therapies—especially for autoimmune diseases such as scleroderma. This past year, that...
About Us
January 7, 2026
A New Year Message from Our Executive Director
As we enter 2026 with momentum, I’m deeply proud of the many achievements we’ve made over the past year, thanks to this extraordinary community—and profoundly grateful for the trust you place in our work. When the year began, a series of actions and spending cuts aimed at the National Institutes...
Research
December 11, 2025
The Scleroderma Research Foundation Collaboration Advances Innovation in Autoimmune Disease Drug Development
We are excited to share a recent interview with Vie Ventures Co-Founders Luke Evnin, PhD (SRF Board Chair) and Steven St. Peter, MD hosted on BiotechTV. The interview highlights:🔹 Why immunology and autoimmunity represent one of the most compelling segments in biotech today🔹How Vie Ventures aims to accelerate therapies for...
View All News & Stories